Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2021-06-22 Regulatory Filings
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC for Graphite Bio, Inc. It is a registration statement under the Securities Act of 1933, related to an initial public offering (IPO) of common stock. The document includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, management, and financial data. Form S-1 is a registration statement used for securities offerings and is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or other categories listed. It is a regulatory filing related to securities registration and offering. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-06-22 English
Regulatory Filings 2021
Regulatory Filings
2021-06-22 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 2 to Form S-1 Registration Statement filed with the SEC by Graphite Bio, Inc. The Form S-1 is a registration statement used by companies planning an initial public offering (IPO) to register their securities with the SEC. The text includes details about the offering, underwriting, risk factors, business overview, management, financial data, and other disclosures typical of an IPO prospectus. It is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or other categories listed. The document is a regulatory filing related to securities registration and offering, which fits best under the category of Regulatory Filings (RNS).
2021-06-21 English
Regulatory Filings 2021
Regulatory Filings
2021-06-16 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC staff regarding comments on a Draft Registration Statement on Form S-1 and its Amendment No. 1. It discusses responses to SEC comments on disclosures and exhibits related to the registration statement. The document is correspondence related to a registration filing, not the registration statement itself or a financial report. It is a regulatory communication responding to SEC review comments, typical of Regulatory Filings (RNS). The document length is under 5,000 characters and is a letter, not a full report or financial statement. Therefore, it fits best under Regulatory Filings (RNS).
2021-06-11 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Graphite Bio, Inc. The Form S-1 is a registration statement used by companies planning an initial public offering (IPO) of securities. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, and other disclosures typical of an IPO registration statement. It is not an annual report, earnings release, or any other type of financial report but a regulatory filing related to securities registration and offering. Therefore, the document fits best under the category of Regulatory Filings (RNS). The document length is substantial and contains detailed disclosures, consistent with an S-1 filing, not a brief announcement or report publication announcement.
2021-06-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.